$1.48 Billion is the total value of Cormorant Asset Management, LP's 64 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 32.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Sell | MIRATI THERAPEUTICS INC | $78,798,000 | +6.0% | 1,075,000 | -38.6% | 5.33% | -11.7% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $70,200,000 | +18.2% | 3,600,000 | -20.0% | 4.74% | -1.6% |
| ANAB | Sell | ANAPTYSBIO INC | $67,206,000 | -4.7% | 920,000 | -16.8% | 4.54% | -20.7% |
| RETA | Sell | REATA PHARMACEUTICALS INC-Acl a | $52,564,000 | +39.0% | 615,000 | -8.8% | 3.55% | +15.7% |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $48,005,000 | +18.9% | 1,411,898 | -4.2% | 3.24% | -1.0% |
| QTNT | Sell | QUOTIENT LTD | $41,446,000 | +42.2% | 4,600,000 | -3.4% | 2.80% | +18.4% |
| ARGX | Sell | ARGENX SEsponsored adr | $34,331,000 | -20.6% | 275,000 | -38.9% | 2.32% | -33.9% |
| MYOK | Sell | MYOKARDIA INC | $31,194,000 | -5.8% | 600,000 | -11.4% | 2.11% | -21.5% |
| AXNX | Sell | AXONICS MODULATION TECH INC | $30,477,000 | +56.9% | 1,272,495 | -1.0% | 2.06% | +30.6% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $29,818,000 | +3.4% | 1,700,000 | -12.6% | 2.02% | -13.9% |
| ZGNX | Sell | ZOGENIX INC | $24,755,000 | +32.8% | 450,000 | -12.0% | 1.67% | +10.5% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $23,062,000 | -31.3% | 1,300,000 | -8.6% | 1.56% | -42.8% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $20,677,000 | +17.5% | 130,000 | -29.2% | 1.40% | -2.2% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $16,800,000 | -6.6% | 500,000 | -8.6% | 1.14% | -22.3% |
| INSP | Sell | INSPIRE MED SYS INC | $14,195,000 | +15.8% | 250,000 | -13.9% | 0.96% | -3.7% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $12,456,000 | +30.7% | 600,000 | -14.3% | 0.84% | +8.9% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $12,190,000 | +47.3% | 500,000 | -13.9% | 0.82% | +22.6% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $11,207,000 | -4.1% | 250,000 | -16.7% | 0.76% | -20.2% |
| ZLAB | Sell | ZAI LAB LTDadr | $10,328,000 | -43.5% | 350,000 | -55.6% | 0.70% | -53.0% |
| RARX | Sell | RA PHARMACEUTICALS INC | $8,960,000 | +11.6% | 400,000 | -9.3% | 0.61% | -7.1% |
| PHAS | Sell | PHASEBIO PHARMACEUTICALS INC | $7,985,000 | +135.3% | 839,642 | -23.5% | 0.54% | +96.4% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $7,929,000 | -49.1% | 90,000 | -58.8% | 0.54% | -57.6% |
| AVRO | Sell | AVROBIO INC | $6,615,000 | -70.7% | 300,000 | -77.9% | 0.45% | -75.6% |
| KNSA | Sell | KINIKSA PHARMACEUTICALS LTD | $4,876,000 | -79.1% | 270,000 | -67.5% | 0.33% | -82.6% |
| TBIO | Sell | TRANSLATE BIO INC | $4,632,000 | +35.9% | 454,549 | -0.0% | 0.31% | +13.0% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $3,902,000 | +50.3% | 100,000 | -17.9% | 0.26% | +25.1% |
| HRTX | Sell | HERON THERAPEUTICS INC | $3,666,000 | -14.7% | 150,000 | -9.5% | 0.25% | -28.9% |
| SRRK | Sell | SCHOLAR ROCK HLDG CORP | $3,361,000 | -30.3% | 178,891 | -14.8% | 0.23% | -42.1% |
| ITRM | Sell | ITERUM THERAPEUTICS PLC | $3,198,000 | +37.0% | 398,300 | -14.5% | 0.22% | +13.7% |
| COLL | Sell | COLLEGIUM PHARMACEUTICAL INC | $3,028,000 | -28.1% | 200,000 | -18.5% | 0.20% | -40.1% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $2,944,000 | -15.6% | 400,000 | -18.1% | 0.20% | -29.7% |
| INCY | Sell | INCYTE CORP | $2,580,000 | -83.9% | 30,000 | -88.1% | 0.17% | -86.6% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,519,000 | -28.7% | 420,555 | -12.0% | 0.17% | -40.8% |
| SLDB | Sell | SOLID BIOSCIENCES INC | $2,300,000 | -86.9% | 250,000 | -61.7% | 0.16% | -89.1% |
| XLRN | Sell | ACCELERON PHARMA INC | $1,863,000 | -12.2% | 40,000 | -17.9% | 0.13% | -26.7% |
| ARQL | Exit | ARQULE INC | $0 | – | -292,095 | -100.0% | -0.07% | – |
| QTRX | Exit | QUANTERIX CORP | $0 | – | -54,945 | -100.0% | -0.08% | – |
| OMER | Exit | OMEROS CORPcall | $0 | – | -181,700 | -100.0% | -0.16% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -194,274 | -100.0% | -0.18% | – |
| MGTX | Exit | MEIRAGTX HOLDGIN PLC | $0 | – | -238,579 | -100.0% | -0.19% | – |
| ASNS | Exit | ARSANIS INC | $0 | – | -1,861,702 | -100.0% | -0.35% | – |
| CFRX | Exit | CONTRAFECT CORP | $0 | – | -2,905,638 | -100.0% | -0.36% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -296,712 | -100.0% | -0.36% | – |
| REPL | Exit | REPLIMUNE GROUP INC | $0 | – | -467,792 | -100.0% | -0.38% | – |
| NKTR | Exit | NEKTAR THERAPEUTICScall | $0 | – | -250,000 | -100.0% | -0.67% | – |
| ZGNX | Exit | ZOGENIX INCcall | $0 | – | -250,000 | -100.0% | -0.74% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCput | $0 | – | -184,000 | -100.0% | -1.43% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -994,287 | -100.0% | -1.55% | – |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -884,916 | -100.0% | -1.84% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -3,481,471 | -100.0% | -3.02% | – |
| TSRO | Exit | TESARO INC | $0 | – | -900,000 | -100.0% | -5.42% | – |
| TSRO | Exit | TESARO INCcall | $0 | – | -1,253,300 | -100.0% | -7.56% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.